Non-alcoholic steatohepatitis (NASH) is a common liver disease that can progress to liver fibrosis, cardiovascular disease, and cancer. In the absence of any approved treatments for it, there is a pressing need for new, effective drugs. In NASH Unmet Need 2017, hepatologists and gastroenterologists reveal the attributes that drive their prescribing and how current treatment options compare across efficacy and safety attributes. Using the Target Product Profile Simulator, we establish physicians’ preference for emerging drugs and assess if these drugs can capitalize on the untapped NASH space.
Primary research: Survey of 60 U.S. and 31 European hepatologists and gastroenterologists fielded in February 2017.
Key companies: Takeda, Merck KGaA, Intercept, Genfit
Key drugs: Actos, Glucophage, Ocaliva, Elafibranor